DEERFIELD MANAGEMENT COMPANY, L.P. Portfolio
Auto-discovered 13F filer (Top-2000 by latest reported value).
SEC 13F CIK: 0001009258
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Q3 2024 · 439 positions · Total reported value $6.31B · Top-10 concentration 57.3% · Updated 2026-10-18
Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR
Turnover: 38.6% · 10 new · 12 cut · 12 exited
Active Share (vs S&P 500): 99.6% · vs QQQ: 99.9% — share of the book that differs from index weights (higher = more active) · ranking
Est. Qtr Return (Q1 2026 → Q2 2026): +17.1% · vs SPY +2.2% · Prev Value $7.59B — last quarter positions weighted by this quarter price moves · ranking
In its Q3 2024 13F filing, DEERFIELD MANAGEMENT COMPANY, L.P. disclosed 439 equity positions with a combined reported value of $6.31B. The filing implies a moderately concentrated portfolio: its ten largest positions account for 57.3% of reported value. HoldingsHub classifies the profile as Mid / Health Tilt / High Turnover.
The largest disclosed positions as of Q3 2024 were NUVL ($2.05B), VTRS ($278.56M), CNC ($199.66M). By sector, the heaviest allocations are Health Care 52.9%, Technology 2.7%. Versus the prior quarter, allocation shifted toward Other (+0.5pp) and away from Health Care (-0.5pp).
Versus the prior quarter, DEERFIELD MANAGEMENT COMPANY, L.P. opened 10 new positions, trimmed 12 and fully exited 12, a turnover rate of 38.6% of positions. The portfolio's overlap with the prior quarter was 29% of names.
The largest new positions opened in Q3 2024 were INDV ($49.65M), BCAX ($45.72M), SVRA ($27.41M).
Of the 12 positions fully exited versus the prior quarter, the largest were GILD ($102.30M), APGE ($12.95M), ITOS ($10.73M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
New Positions (Q3 2024)
- INDV INDIVIOR PHARMACEUTICALS INC · $49.65M
- BCAX BICARA THERAPEUTICS INC · $45.72M
- SVRA Savara Inc · $27.41M
- ZBIO ZENAS BIOPHARMA INC COM · $26.44M
- PCVX VAXCYTE INC · $25.71M
- DYN DYNE THERAPEUTICS INC · $15.65M
- RXRX RECURSION PHARMACEUTICALCLASS A · $15.26M
- CON CONCENTRA GROUP HOLDINGS PAREN COMMON STOCK · $14.53M
Fully Exited (vs previous quarter)
- GILD GILEAD SCIENCES INC · prev qtr: $102.30M
- APGE APOGEE THERAPEUTICS INC · prev qtr: $12.95M
- ITOS ITEOS THERAPEUTICS INC · prev qtr: $10.73M
- SLDB SOLID BIOSCIENCES INC COM NEW · prev qtr: $9.89M
- EYPT EYEPOINT INC · prev qtr: $7.64M
- GUTS FRACTYL HEALTH INC · prev qtr: $3.56M
- CABA CABALETTA BIO INC · prev qtr: $3.47M
- DRI DARDEN RESTAURANTS INC · prev qtr: $2.17M
Insider Transactions (Form 4)
Latest DEERFIELD MANAGEMENT COMPANY, L.P. buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
| Transaction date | Activity | Security | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-07-15 | D | Nuvalent, Inc. | 3,444 | $124.00 | SEC filing |
| 2026-07-15 | U | Nuvalent, Inc. | 5,146 | $124.00 | SEC filing |
| 2026-07-15 | D | Nuvalent, Inc. | 650,000 | $124.00 | SEC filing |
| 2026-07-15 | D | Nuvalent, Inc. | 8,299,225 | $124.00 | SEC filing |
| 2026-06-16 | Award | Nuvalent, Inc. | 3,444 | — | SEC filing |
| 2026-06-11 | Conversion | Parabilis Medicines, Inc. | 407,132 | — | SEC filing |
| 2026-06-11 | Conversion | Parabilis Medicines, Inc. | 260,992 | — | SEC filing |
| 2026-06-11 | Conversion | Parabilis Medicines, Inc. | 149,238 | — | SEC filing |
Fund Profile
Deerfield Management Company, L.P. is a New York-based hedge fund founded by Marianne and James Chadwin, known for its quantitative and fundamental research approach focused primarily on healthcare and biotechnology investments.
Investment Approach
Combines quantitative analysis with fundamental research
Specializes in healthcare and biotechnology sectors
Utilizes both public and private investment strategies
Asset Classes & Strategy
Primarily focused on long/short equity positions
Specializes in healthcare and biotechnology investments
Also invests in other sectors with strong fundamental research
Key Personnel
Marianne Chadwin (Co-founder)
James Chadwin (Co-founder)
Team of experienced portfolio managers and researchers
AUM & Performance
Manages approximately $19.1 billion in assets under management
Performance data not publicly disclosed
All information is based on publicly available SEC filings and company disclosures.
Sector Allocation
| # | Company | Shares | Value | Weight | Allocation | Change |
|---|---|---|---|---|---|---|
| 1 |
|
19.99M | $2.05B | 32.42% | Hold | |
| 2 |
|
23.99M | $278.56M | 4.42% | Add | |
| 3 |
|
2.65M | $199.66M | 3.17% | Hold | |
| 4 |
|
3.41M | $170.29M | 2.70% | Add | |
| 5 |
|
7.85M | $166.53M | 2.64% | Add | |
| 6 |
|
174.36M | $165.76M | 2.63% | Add | |
| 7 |
|
11.08M | $160.63M | 2.55% | Hold | |
| 8 |
|
1.32M | $151.70M | 2.40% | Add | |
| 9 |
|
21.23M | $139.07M | 2.20% | Hold | |
| 10 |
|
4.95M | $138.11M | 2.19% | Hold | |
| 11 |
|
2.91M | $132.09M | 2.09% | Reduce | |
| 12 |
|
10.85M | $128.31M | 2.03% | Hold | |
| 13 |
|
6.23M | $123.85M | 1.96% | Reduce | |
| 14 |
|
9.71M | $109.06M | 1.73% | Reduce | |
| 15 |
|
15.61M | $106.01M | 1.68% | Hold | |
| 16 |
|
5.41M | $105.74M | 1.68% | Hold | |
| 17 |
|
70.00M | $103.04M | 1.63% | Hold | |
| 18 |
|
2.59M | $82.18M | 1.30% | Add | |
| 19 |
|
4.91M | $77.07M | 1.22% | Reduce | |
| 20 |
|
1.92M | $73.02M | 1.16% | Add | |
| 21 |
|
8.14M | $61.83M | 0.98% | Hold | |
| 22 |
|
1.78M | $57.40M | 0.91% | Reduce | |
| 23 |
|
874.80K | $55.01M | 0.87% | Reduce | |
| 24 |
|
3.28M | $54.91M | 0.87% | Hold | |
| 25 |
|
151.57K | $50.71M | 0.80% | Hold | |
| 26 |
|
1.02M | $50.28M | 0.80% | Hold | |
| 27 |
|
5.09M | $49.65M | 0.79% | New | |
| 28 |
|
1.78M | $47.54M | 0.75% | Reduce | |
| 29 |
|
1.80M | $45.72M | 0.72% | New | |
| 30 |
|
614.89K | $44.22M | 0.70% | Reduce | |
| 31 |
|
1.41M | $40.62M | 0.64% | Hold | |
| 32 |
|
3.74M | $40.44M | 0.64% | Hold | |
| 33 |
|
145.00K | $39.88M | 0.63% | Add | |
| 34 |
|
5.00M | $39.48M | 0.63% | Hold | |
| 35 |
|
2.73M | $38.50M | 0.61% | Hold | |
| 36 |
|
2.03M | $37.63M | 0.60% | Add | |
| 37 |
|
2.82M | $37.62M | 0.60% | Hold | |
| 38 |
|
844.41K | $37.06M | 0.59% | Hold | |
| 39 |
|
2.62M | $36.46M | 0.58% | Reduce | |
| 40 |
|
1.51M | $34.07M | 0.54% | Add | |
| 41 |
|
850.70K | $32.10M | 0.51% | Add | |
| 42 |
|
9.07M | $30.10M | 0.48% | Add | |
| 43 |
|
3.03M | $28.19M | 0.45% | Add | |
| 44 |
|
6.71M | $27.58M | 0.44% | Hold | |
| 45 |
|
6.47M | $27.41M | 0.43% | New | |
| 46 |
|
1.58M | $26.76M | 0.42% | Add | |
| 47 |
|
663.85K | $26.53M | 0.42% | Hold | |
| 48 |
|
1.56M | $26.44M | 0.42% | New | |
| 49 |
|
240.22K | $26.36M | 0.42% | Hold | |
| 50 |
|
225.00K | $25.71M | 0.41% | New | |
FAQ
What did DEERFIELD MANAGEMENT COMPANY, L.P. buy in 2024-Q3?
In its 2024-Q3 13F filing, DEERFIELD MANAGEMENT COMPANY, L.P. reported 439 equity positions worth $6.31B in aggregate; its largest disclosed positions were NUVL ($2.05B), VTRS ($278.56M), CNC ($199.66M).
How large is DEERFIELD MANAGEMENT COMPANY, L.P.'s portfolio?
DEERFIELD MANAGEMENT COMPANY, L.P. reported $6.31B of long equity holdings across 439 positions as of 2024-Q3. Top-10 holdings account for 57.3% of reported value.
What is DEERFIELD MANAGEMENT COMPANY, L.P.'s investment style?
HoldingsHub classifies the portfolio as Mid / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.